Lymphoma, B-Cell Clinical Trials

22 recruiting

Frequently Asked Questions

Common questions about Lymphoma, B-Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 1Phase 2

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC439 enrolled31 locationsNCT05421663
Recruiting
Phase 3

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLymphoma, B-Cell+6 more
Lyell Immunopharma, Inc.400 enrolled39 locationsNCT07188558
Recruiting
Phase 1

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Lymphoma, B-Cell
Celgene174 enrolled40 locationsNCT04884035
Recruiting
Early Phase 1

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Lymphoma, B-Cell
Canadian Cancer Trials Group18 enrolled4 locationsNCT04161248
Recruiting
Not Applicable

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+2 more
Hua-Jay J Cherng, MD40 enrolled1 locationNCT06693830
Recruiting
Phase 1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Lymphoma, B-CellChronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)+1 more
Umoja Biopharma106 enrolled8 locationsNCT06528301
Recruiting
Not Applicable

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Multiple MyelomaLymphoma, B-CellB-cell Lymphoma+5 more
University Health Network, Toronto144 enrolled1 locationNCT06485076
Recruiting

Family Study of Lymphoproliferative Disorders

Multiple MyelomaLymphoma, Non-HodgkinLymphoma, B-Cell+2 more
Mayo Clinic3,000 enrolled1 locationNCT00626496
Recruiting
Not Applicable

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoma, B-Cell+3 more
Memorial Sloan Kettering Cancer Center48 enrolled2 locationsNCT05940272
Recruiting
Phase 1

Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

Lymphoma, B-Cell
Bantam Pharmaceuticals24 enrolled1 locationNCT06792734
Recruiting

Early Assessment of Cardiac Function After Treatment With CAR-T Cells

Acute Lymphoblastic LeukemiaMultiple MyelomaHematologic Malignancy+2 more
Assistance Publique - Hôpitaux de Paris60 enrolled1 locationNCT06350994
Recruiting

Prospective Observational Study of Diffuse Large-cell B Lymphoma

Lymphoma, B-Cell
Grand Hôpital de Charleroi50 enrolled1 locationNCT06241729
Recruiting
Phase 1Phase 2

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Lymphoma, Non-HodgkinLymphoma, B-CellLarge B-cell Lymphoma+3 more
Cancer Research UK84 enrolled7 locationsNCT06045910
Recruiting

Study of CAR-T Therapy in Older Patients

High-grade B-cell LymphomaMultiple MyelomaLymphoma+3 more
Memorial Sloan Kettering Cancer Center154 enrolled1 locationNCT04300998
Recruiting
Phase 2

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

LymphomaLymphoma, B-Cell
Jennifer Amengual30 enrolled2 locationsNCT06954805
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Lymphoma, T-CellLymphoma, B-Cell
Step Pharma, SAS180 enrolled15 locationsNCT05463263
Recruiting
Phase 1Phase 2

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

AML (Acute Myelogenous Leukemia)B-ALLMyeloma, Multiple+3 more
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting
Not Applicable

CD-19 CAR-T Cell for Pediatric ALL or Lymphoma

Lymphoma, B-CellAcute Lymphoblastic Leukemia, Pediatric
Hong Kong Children's Hospital18 enrolled1 locationNCT06866873
Recruiting
Not Applicable

CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

Lymphoma, B-Cell
Shanxi Bethune Hospital15 enrolled1 locationNCT06850285
Recruiting
Phase 1

Phase Ib Clinical Study of Keynatinib

Lymphoma, B-Cell
Medolution Ltd.75 enrolled4 locationsNCT04807881